AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.52 |
Market Cap | 4.54M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -11.35 |
PE Ratio (ttm) | -0.13 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.59 |
Volume | 107,375 |
Avg. Volume (20D) | 1,427,395 |
Open | 1.60 |
Previous Close | 1.58 |
Day's Range | 1.50 - 1.60 |
52-Week Range | 1.41 - 18.72 |
Beta | undefined |
About SONN
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the ...
Analyst Forecast
According to 2 analyst ratings, the average rating for SONN stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 2416.56% from the latest price.